Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

NCT00424840 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Lung Cancer

Interventions

DRUG: Bortezomib 1.3 mg/m2
DRUG: Bortezomib 1.6 mg/m2
DRUG: Bortezomib 1.8 mg/m2
DRUG: Carboplatin AUC 6
DRUG: Bevacizumab
DRUG: Taxotere

Sponsor

University of Massachusetts, Worcester

Collaborators

[object Object]
[object Object]